13 januari 2026 Sweden
In an interview with BioStock, board member Karin Rosén discusses how Nobel Prize–recognized research on peripheral immune tolerance underpins Diamyd Medical’s strategy and its relevance for autoimmune diabetes. She also outlines what preserving patients’ own insulin production could mean for disease modification as the company approaches the interim phase III DIAGNODE-3 readout in March 2026. Read the article here
|
9 januari 2026 Sweden
In an interview with BioStock, CEO Ulf Hannelius and board member Karin Rosén discuss what accelerated timeline for its phase III study DIAGNODE 3 could mean going forward, what to expect from the preliminary readout in March 2026, and how the 2025 Nobel Prize in Medicine may be linked to Diamyd Medical’s work. See the interview here
|